Background: Insect bite hypersensitivity (IBH) is an eosinophilic allergic dermatitis of horses caused by type I/IVb reactions against mainly Culicoides bites. The vaccination of IBH-affected horses with equine IL-5 coupled to the Cucumber mosaic virus-like particle (eIL-5-CuMVTT) induces IL-5-specific auto-antibodies, resulting in a significant reduction in eosinophil levels in blood and clinical signs. Objective: the preclinical and clinical safety of the eIL-5-CuMVTT vaccine. Methods: The B cell responses were assessed by longitudinal measurement of IL-5- and CuMVTT-specific IgG in the serum and plasma of vaccinated and unvaccinated horses. Further, peripheral blood mononuclear cells (PBMCs) from the same horses were re-stimulated in vitro for the proliferation and IFN-γ production of specific T cells. In addition, we evaluated longitudinal kidney and liver parameters and the general blood status. An endogenous protein challenge was performed in murine IL-5-vaccinated mice. Results: The vaccine was well tolerated as assessed by serum and cellular biomarkers and also induced reversible and neutralizing antibody titers in horses and mice. Endogenous IL-5 stimulation was unable to re-induce anti-IL-5 production. The CD4+ T cells of vaccinated horses produced significantly more IFN-γ and showed a stronger proliferation following stimulation with CuMVTT as compared to the unvaccinated controls. Re-stimulation using E. coli-derived proteins induced low levels of IFNγ+CD4+ cells in vaccinated horses; however, no IFN-γ and proliferation were induced following the HEK-eIL-5 re-stimulation. Conclusions: Vaccination using eIL-5-CuMVTT induces a strong B-cell as well as CuMVTT-specific T cell response without the induction of IL-5-specific T cell responses. Hence, B-cell unresponsiveness against self-IL-5 can be bypassed by inducing CuMVTT carrier-specific T cells, making the vaccine a safe therapeutic option for IBH-affected horses.
Urticaria, independent of or associated with allergies, is commonly seen in horses and often shows a high reoccurrence rate. Managing these horses is discouraging, and efficient treatment options are lacking. Due to an incidental finding in a study on horses affected by insect bite hypersensitivity using the eosinophil-targeting eIL-5-CuMV-TT vaccine, we observed the prevention of reoccurring seasonal urticaria in four subsequent years with re-vaccination. In an exploratory case series of horses affected with non-seasonal urticaria, we aimed to investigate the role of eosinophils in urticaria. Skin punch biopsies for histology and qPCR of eosinophil associated genes were performed. Further, two severe, non-seasonal, recurrent urticaria-affected horses were vaccinated using eIL-5-CuMV-TT, and urticaria flare-up was followed up with re-vaccination for several years. Eotaxin-2, eotaxin-3, IL-5, CCR5, and CXCL10 showed high sensitivity and specificity for urticarial lesions, while eosinophils were present in 50% of histological tissue sections. The eIL-5-CuMV-TT vaccine reduced eosinophil counts in blood, cleared clinical signs of urticaria, and even prevented new episodes of urticaria in horses with non-seasonal recurrent urticaria. This indicates that eosinophils play a leading role in urticaria in horses, and targeting eosinophils offers an attractive new treatment option, replacing the use of corticosteroids.
Summary: Chronic pruritus is defined as prolonged itching symptoms associated with a variety of skin conditions. These pruritic conditions clinically manifest in a dermatitis phenotype and commonly are of allergic origin with hypersensitivities towards environmental allergens. Interleukin‐31 (IL‐31) is a common player in allergic pruritus across species. The objective of the study was evaluation of the clinical efficacy of a therapeutic vaccine targeting IL‐31 in horses with chronic pruritus of unknown origin (CPUO) and that could not be explained by insect bite hypersensitivity (IBH). This consecutive case series pilot study included client‐owned horses with a long history of CPUO. Four horses affected by year‐round CPUO were vaccinated with a vaccine consisting of equine IL‐31 (eIL‐31) covalently coupled to a virus‐like particle (VLP) derived from cucumber mosaic virus containing a tetanus toxoid universal T cell epitope (CuMV TT ). Clinical signs and pruritic behaviour were documented by photography and owner questionnaire pre and post vaccination. In addition, in three CPUO horses, levels of IL‐31, thymic stromal lymphopoietin (TSLP) and monocyte chemoattractant protein 1 (MCP‐1) were quantified from skin punch biopsies. IL‐31, TSLP and MCP‐1 levels were upregulated in pruritic, alopecic skin lesions compared to healthy skin of the same horse. Clinical signs and pruritic behaviour improved in all four horses upon vaccination with eIL‐31‐CuMV TT vaccine. The vaccine was well tolerated without safety concerns throughout the study. The main limitations of this study are the absence control treated horses and allergy diagnostics. It was concluded that Anti‐IL‐31 therapy might be applied as an allergen‐independent treatment option for horses with CPUO overcoming the challenges of identifying the allergic trigger.
Background: Recurrent urticaria is common in horses. The pathophysiology is poorly understood and treatment options are limited. Often, only glucocorticoids are effective for controlling clinical signs, albeit with potential adverse effects. Studies investigating new treatments need a validated objective scoring system for the grading of skin lesions to assess response.Hypothesis/Objectives: The aims were to investigate inter‐ and intraobserver reliability of the Equine Urticaria Activity Score (EqUAS) for the grading of skin lesions in horses with recurrent urticaria, and to examine agreement between experienced and inexperienced observers.Animals: Forty privately owned horses enrolled in a therapeutic clinical trial.Materials and Methods: Ten standardised photographs of both sides of the body of each horse were used to create 40 individual datasets. Five masked observers graded the photographs according to the EqUAS for calculation of interobserver reliability. Intraobserver reliability was calculated from two observers each grading the photographs twice. Scores were evaluated for reliability with Pearson's correlation (r) and for agreement with the intraclass correlation coefficient (ICC).Results: Interobserver reliability was excellent with r = 0.9036–0.9600 (p < 0.0001). Intraobserver reliability and agreement also were excellent with r = 0.98 for each observer (p < 0.0001) and ICC = 0.945. Correlation and agreement between experienced and inexperienced observers were excellent (r = 0.9615 [p < 0.0001] and ICC = 0.941).Conclusions and Clinical Relevance: The EqUAS showed excellent intra‐ and interobserver reliability for the evaluation of skin lesions of horses with chronic recurrent urticaria. It can be a useful tool in clinical studies.
1 July 2026 in Journal of Veterinary Internal Medicine
Insect bite hypersensitivity (IBH) is the most common allergic skin disease in horses, but existing clinical scoring systems lack extensive validation, limiting standardized disease monitoring and therapeutic evaluation. Develop and validate a standardized, sensitive, and reproducible clinical scoring system for IBH in horses. Forty-four privately-owned horses with clinically diagnosed IBH examined under field conditions in Switzerland. In this prospective field validation study, the equine IBH severity score (EqIS) integrates a lesion severity score and an area score using a multiplicative algorithm. Six trained evaluators assessed horses independently. Primary outcomes were intra- and interobserver reliability of the lesion severity score and EqIS assessed using intraclass correlation coefficients (ICC). Secondary analyses included agreement of the area score (Pearson correlation), correlations between owner-reported visual analog scale (VAS) scores and EqIS, and comparison between EqIS and a simplified EqIS developed for field use. Intraobserver reliability was excellent (ICC = 0.995 for the lesion severity score and 0.989 for EqIS), and interobserver reliability was similarly high (ICC = 0.98 for both). The area score showed strong interobserver agreement (Pearson r = 0.86-0.94). Owner VAS scores correlated moderately with EqIS (ρ = 0.49-0.51) and strongly with each other (ρ = 0.88). The simplified EqIS demonstrated strong agreement with the validated version (R2 = 0.86). The EqIS is the first extensively validated IBH-specific scoring system and demonstrates excellent reproducibility across evaluators. It provides an objective tool for standardized disease assessment and therapeutic monitoring, whereas the simplified EqIS offers a practical alternative for routine field use.